The vice president of Neuroscience and Vaccines at Takeda discusses the clinical significance of oveporexton's FDA approval ...
In recognition of SMA Awareness Month, held annually throughout August, NeurologyLive® reviews the investigational agents ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
In recognition of Spinal Muscular Atrophy (SMA) Awareness Month, held annually in August, this month’s spotlight is the phase 3 program for Biogen’s salanersen, formally known as BIIB115, which is an ...
The American Heart Association (AHA) and American Stroke Association (ASA) have published the "2026 Guideline for Adult ...
Cellenkos’ investigational allogeneic, cord blood-derived T-regulatory cell therapy is being evaluated in a phase 1/1b study ...
Brian Lin, PhD, Research Director at the Muscular Dystrophy Association, commented on the first-ever clinical trial framework ...
Riley Bove, MD, an associate professor of neurology at the University of California, San Francisco, discussed phase 4 findings from the MINORE and SOPRANINO studies that examined ocrelizumab exposure ...
Dustin Gable, MD, PhD, a pediatric neuromuscular neurologist at Johns Hopkins Medicine, discussed why bulbar dysfunction ...
Nestor Galvez-Jimenez, MD, a neurologist at Baptist Health Miami Neuroscience Institute, discussed how advancements have changed the landscape of care for patients living with spinal muscular atrophy.
The PDUFA date moved to November 22, 2026, because CBER accepted a major BLA amendment incorporating additional HOPE-3 follow ...
The treatment landscape for chronic inflammatory demyelinating polyneuropathy has changed considerably over the past several years, with targeted therapies expanding the options available to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results